WO2012095548A3 - Compuestos para el tratamiento de enfermedades neurodegenerativas - Google Patents

Compuestos para el tratamiento de enfermedades neurodegenerativas Download PDF

Info

Publication number
WO2012095548A3
WO2012095548A3 PCT/ES2012/070020 ES2012070020W WO2012095548A3 WO 2012095548 A3 WO2012095548 A3 WO 2012095548A3 ES 2012070020 W ES2012070020 W ES 2012070020W WO 2012095548 A3 WO2012095548 A3 WO 2012095548A3
Authority
WO
WIPO (PCT)
Prior art keywords
dream
inhibitors
treating neurodegenerative
neurodegenerative diseases
treating
Prior art date
Application number
PCT/ES2012/070020
Other languages
English (en)
French (fr)
Other versions
WO2012095548A2 (es
WO2012095548A9 (es
Inventor
Britt MELLSTRÖM
Diego VILLAR LOZANO
Mara Dierssen Sotos
José Ramón NARANJO OROVIO
Original Assignee
Centro De Investigación Biomédica En Red De Enfermedades Neurodegenerativas (Ciberned)
Consejo Superior De Investigaciones Científicas
Fundació Privada Centre De Regulació Genómica (Crg)
Fundación Cien
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Centro De Investigación Biomédica En Red De Enfermedades Neurodegenerativas (Ciberned), Consejo Superior De Investigaciones Científicas, Fundació Privada Centre De Regulació Genómica (Crg), Fundación Cien filed Critical Centro De Investigación Biomédica En Red De Enfermedades Neurodegenerativas (Ciberned)
Publication of WO2012095548A2 publication Critical patent/WO2012095548A2/es
Publication of WO2012095548A3 publication Critical patent/WO2012095548A3/es
Publication of WO2012095548A9 publication Critical patent/WO2012095548A9/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/451—Non condensed piperidines, e.g. piperocaine having a carbocyclic group directly attached to the heterocyclic ring, e.g. glutethimide, meperidine, loperamide, phencyclidine, piminodine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La invención se relaciona con un método para el tratamiento de enfermedades neurodegenerativas y, en particular, de la enfermedad de Huntingíon, mediante el uso de inhibidores de la proteína DREAM y, en particular, de distintas moléculas de la familia de las glinidas tales como la Repaglinida.
PCT/ES2012/070020 2011-01-13 2012-01-13 Compuestos para el tratamiento de enfermedades neurodegenerativas WO2012095548A2 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
ES201130033 2011-01-13
ESP201130033 2011-01-13

Publications (3)

Publication Number Publication Date
WO2012095548A2 WO2012095548A2 (es) 2012-07-19
WO2012095548A3 true WO2012095548A3 (es) 2012-11-15
WO2012095548A9 WO2012095548A9 (es) 2012-12-27

Family

ID=45815578

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/ES2012/070020 WO2012095548A2 (es) 2011-01-13 2012-01-13 Compuestos para el tratamiento de enfermedades neurodegenerativas

Country Status (1)

Country Link
WO (1) WO2012095548A2 (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2578377B1 (es) * 2014-12-22 2017-05-04 Consejo Superior De Investigaciones Científicas (Csic) Compuestos moduladores del sensor neuronal de calcio dream y sus usos terapéuticos.

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1774972A1 (en) * 2005-10-14 2007-04-18 Alltech, Inc. Use of selenium compounds, especially selenium yeasts in the treatment of Alzheimer, neurodegenerative diseases and diabetes
EP1884244A1 (en) * 2006-08-02 2008-02-06 Assistance Publique - Hopitaux de Paris Potassium channel ligands for treating diabetes and neuropsychological dysfunction
WO2008046014A1 (en) * 2006-10-12 2008-04-17 Remedy Pharmaceuticals, Inc. Treatment of alzheimer's disease using compounds that reduce the activity of non-selective ca++- activated atp-sensitive cation channels regulated by sur1 receptors

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3347565A1 (de) 1983-12-30 1985-07-11 Thomae Gmbh Dr K Neue phenylessigsaeurederivate, diese verbindungen enthaltende arzneimittel und verfahren zu ihrer herstellung
JPS6354321A (ja) 1985-03-27 1988-03-08 Ajinomoto Co Inc 血糖降下剤
CA1310924C (en) 1986-04-24 1992-12-01 Francis P. Mccormick Infective drug delivery system
US4902505A (en) 1986-07-30 1990-02-20 Alkermes Chimeric peptides for neuropeptide delivery through the blood-brain barrier
US4987071A (en) 1986-12-03 1991-01-22 University Patents, Inc. RNA ribozyme polymerases, dephosphorylases, restriction endoribonucleases and methods
US4904582A (en) 1987-06-11 1990-02-27 Synthetic Genetics Novel amphiphilic nucleic acid conjugates
US4970154A (en) 1987-10-09 1990-11-13 Baylor College Of Medicine Method for inserting foreign genes into cells using pulsed radiofrequency
US5672344A (en) 1987-12-30 1997-09-30 The Regents Of The University Of Michigan Viral-mediated gene transfer system
US5176996A (en) 1988-12-20 1993-01-05 Baylor College Of Medicine Method for making synthetic oligonucleotides which bind specifically to target sites on duplex DNA molecules, by forming a colinear triplex, the synthetic oligonucleotides and methods of use
US5256775A (en) 1989-06-05 1993-10-26 Gilead Sciences, Inc. Exonuclease-resistant oligonucleotides
US5399346A (en) 1989-06-14 1995-03-21 The United States Of America As Represented By The Department Of Health And Human Services Gene therapy
US5262165A (en) 1992-02-04 1993-11-16 Schering Corporation Transdermal nitroglycerin patch with penetration enhancers
US5264564A (en) 1989-10-24 1993-11-23 Gilead Sciences Oligonucleotide analogs with novel linkages
US5676954A (en) 1989-11-03 1997-10-14 Vanderbilt University Method of in vivo delivery of functioning foreign genes
US6010715A (en) 1992-04-01 2000-01-04 Bertek, Inc. Transdermal patch incorporating a polymer film incorporated with an active agent
US5631236A (en) 1993-08-26 1997-05-20 Baylor College Of Medicine Gene therapy for solid tumors, using a DNA sequence encoding HSV-Tk or VZV-Tk
US5484720A (en) 1994-09-08 1996-01-16 Genentech, Inc. Methods for calcium phosphate transfection
JPH11506722A (ja) 1995-06-07 1999-06-15 ベイラー・カレッジ・オブ・メディスン 細胞に核酸を送達するための核酸運搬体
UA48973C2 (uk) 1995-06-07 2002-09-16 Орто-Макнейл Фармасьютікалз Інк. Трансдермальний пластир на основі 17-деацетилноргестимату для попередження овуляції
US5679559A (en) 1996-07-03 1997-10-21 University Of Utah Research Foundation Cationic polymer and lipoprotein-containing system for gene delivery
US5948433A (en) 1997-08-21 1999-09-07 Bertek, Inc. Transdermal patch
WO2006053067A2 (en) 2004-11-09 2006-05-18 Prestwick Pharmaceuticals, Inc. Combination of amantadine and a tetrabenazine compound for treating hyperkinetic disorders
GB0514501D0 (en) 2005-07-14 2005-08-24 Cambridge Lab Ireland Ltd Pharmaceutical compounds

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1774972A1 (en) * 2005-10-14 2007-04-18 Alltech, Inc. Use of selenium compounds, especially selenium yeasts in the treatment of Alzheimer, neurodegenerative diseases and diabetes
EP1884244A1 (en) * 2006-08-02 2008-02-06 Assistance Publique - Hopitaux de Paris Potassium channel ligands for treating diabetes and neuropsychological dysfunction
WO2008046014A1 (en) * 2006-10-12 2008-04-17 Remedy Pharmaceuticals, Inc. Treatment of alzheimer's disease using compounds that reduce the activity of non-selective ca++- activated atp-sensitive cation channels regulated by sur1 receptors

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
DONG-GYU JO ET AL: "Induction of pro-apoptotic calsenilin/DREAM/KChIP3 in Alzheimer's disease and cultured neurons after amyloid-beta exposure.", JOURNAL OF NEUROCHEMISTRY, vol. 88, no. 3, February 2004 (2004-02-01), pages 604 - 611, XP002674313, ISSN: 0022-3042 *

Also Published As

Publication number Publication date
WO2012095548A2 (es) 2012-07-19
WO2012095548A9 (es) 2012-12-27

Similar Documents

Publication Publication Date Title
HK1258231A1 (zh) 治療阿爾茨海默氏症、亨廷頓氏症、孤獨症和其他障礙的方法
WO2013061161A3 (en) New combination therapies for treating neurological disorders
WO2012062925A3 (en) Compounds and methods for treating pain
GB2492487B (en) Cannabinoids for use in the treatment of neurodegenerative diseases or disorders
WO2012177603A3 (en) Metalloenzyme inhibitor compounds
MX2022004300A (es) Composicion y metodo para el diagnostico y tratamiento de enfermedades asociadas con la degeneracion de neuritas.
WO2012097213A3 (en) Methods for diagnosing and treating eye-length related disorders
WO2012149478A3 (en) Agents useful for treating friedreich's ataxia and other neurodegenerative diseases
WO2012154695A3 (en) Treatment of polycystic disease
WO2013101451A8 (en) Method of treating alveolar bone loss through the use of anti-sclerostin antibodies
WO2012170918A3 (en) Methods of treatment for retinal diseases
BR112013031117A2 (pt) scilo-inositol para o tratamento de transtornos comportamentais e psiquiátricos.
SG11201402607VA (en) Method for purifying 1,3-butadiene
IL232710A0 (en) l-serine preparations, methods and uses for the treatment of neurodegenerative diseases and disorders
WO2013090635A3 (en) Composition and method for the diagnosis and treatment of iron-related disorders
WO2012112674A3 (en) Compounds and methods of use thereof for treating neurodegenerative disorders
CL2014000119A1 (es) Sal de (r)-3-(6-(4-metilfenil)-piridin-3-iloxi)-1-aza-biciclo[2.2.2]octano; composicion farmaceutica; metodo de preparacion; proceso de prodcucion de la sal y sus precursores; y metodo para prevencion, tratamiento y/o retraso de la progresion de una enfermedad o condicion tal como trastornos psiquiatricos o neurodegenerativos.
HK1192726A1 (en) 1,2,4-thiadiazol-5-ylpiperazine derivatives useful in the treatment of neurodegenerative diseases 124--5-
EP2750606A4 (en) METHOD FOR THE DIAGNOSIS AND TREATMENT OF NEUROLOGICAL AND NEURODEEGENERATIVE DISEASES, DISORDERS AND RELATED METHODS
BR112014004224A2 (pt) aparelhos e métodos para tratamento de estacas de caules de cana-de açúcar
CA2851761C (en) Method of diagnosis, prognostic or treatment of neurodegenerative diseases
HK1186986A1 (zh) 治療皮膚病的方法
WO2014028397A3 (en) Laquinimod for treatment of gaba mediated disorders
WO2013033004A3 (en) Metalloenzyme inhibitor compounds
WO2012103282A3 (en) Methods and compositions for treating alzheimer's disease

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 12708359

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 12708359

Country of ref document: EP

Kind code of ref document: A2